Help appealing denials for this first-in-class oral antibiotic for gonorrhea.

Appeal Your Nuzolvence Denial

Get access to this new oral treatment for uncomplicated gonorrhea.

Understanding Your Nuzolvence (zoliflodacin) Denial

Nuzolvence (zoliflodacin) is the first spiropyrimidinetrione antibiotic approved for uncomplicated urogenital gonorrhea. With increasing antibiotic resistance in gonorrhea, new treatment options are critically needed. This single-dose oral treatment offers an important alternative when other antibiotics may not be effective.

Common Reasons for Denial

! Prior authorization required
! Must try ceftriaxone first
! Culture and sensitivity not provided
! Not medically necessary
! New drug with limited coverage policies
! Single-dose treatment cost concerns

How We Help

We help you document your gonorrhea diagnosis, any antibiotic allergies, prior treatment failures, and why Nuzolvence is the appropriate choice for your infection.

Start your Nuzolvence appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic with a novel mechanism of action.

✓ Clinical trials demonstrated non-inferiority to ceftriaxone plus azithromycin for uncomplicated gonorrhea.

✓ Antibiotic-resistant gonorrhea is a growing public health threat requiring new treatment options.

✓ Single-dose oral treatment improves adherence compared to multi-dose regimens.

Frequently Asked Questions

Nuzolvence may be appropriate if you have allergies to cephalosporins or other first-line antibiotics, if there's concern about antibiotic resistance, or if you prefer oral over injectable treatment.

Nuzolvence is specifically approved for uncomplicated urogenital gonorrhea. You may still need testing and treatment for other STIs like chlamydia.

Ready to Fight Your Nuzolvence (zoliflodacin) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Innoviva Specialty Therapeutics. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.